Annexon Inc. (ANNX) is threading together a trio of late-stage programs that could reshape treatment options across neurology, ophthalmology, and autoimmunity. With global filings, pivotal data, and mechanistic innovation converging through 2026, the company is building momentum around a single molecular target, C1q, and translating it into three distinct therapeutic strategies.
Tanruprubart for Guillain-Barré Syndrome: Regulatory Engagement Underway
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.